Fournier's gangrene and diabetic ketoacidosis with lower-than-anticipated glucose levels associated with SGLT-2 inhibitor: A double trouble
| Autor: | Attar Ismail, Dheeraj Kapoor, Sonali Vadi |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
0301 basic medicine
Gangrene medicine.medical_specialty Diabetic ketoacidosis business.industry Urinary system 030106 microbiology General Medicine medicine.disease Gastroenterology Pathophysiology Ketoacidosis 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Diabetes mellitus Internal medicine Scrotum Empagliflozin Medicine 030212 general & internal medicine business |
| Zdroj: | Medical Journal Armed Forces India. 79:225-228 |
| ISSN: | 0377-1237 |
| Popis: | Empagliflozin has a demonstrated cardiovascular benefit. It is co-prescribed as a glucose-lowering medication in patients with type II diabetes mellitus. Herein, we discuss dual-emergency side-effects, Fournier's gangrene (FG) and diabetic ketoacidosis with lower-than-anticipated glucose levels in a patient on Empagliflozin, a sodium-glucose transport protein 2 inhibitor (SGLT-2i). The pathophysiologic mechanism of FG in correlation with SGLT-2i is not yet elucidated. SGLT-2i increase predisposition to genital mycotic and urinary infections, a mechanism favouring FG. A patient with type II diabetes mellitus on SGLT-2i presented with acute necrotic infection of the scrotum and simultaneous diabetic ketoacidosis with lower-than-anticipated glucose levels. This dual emergency was managed with debridement and medical treatment on lines of diabetes ketoacidosis, respectively. A re-look at this group of glucose-lowering medications from bedside towards benchtop research may help to prod into any other mechanistic basis of these life-threatening clinical occurrences. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect